Published in J Clin Invest on December 01, 2002
Histamine influences body temperature by acting at H1 and H3 receptors on distinct populations of preoptic neurons. J Neurosci (2010) 1.09
Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol (2004) 1.03
Mouse behavioural analysis in systems biology. Biochem J (2005) 0.99
Brain regulation of energy balance and body weight. Rev Endocr Metab Disord (2013) 0.96
Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am J Pathol (2010) 0.95
Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A (2006) 0.95
Histamine H3 receptors aggravate cerebral ischaemic injury by histamine-independent mechanisms. Nat Commun (2014) 0.86
Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology (2013) 0.82
H1-antihistamines exacerbate high-fat diet-induced hepatic steatosis in wild-type but not in apolipoprotein E knockout mice. Am J Physiol Gastrointest Liver Physiol (2014) 0.79
Loss of histaminergic modulation of thermoregulation and energy homeostasis in obese mice. Neuroscience (2012) 0.79
Histamine H(3) receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibility. PLoS One (2013) 0.76
Histamine receptor signaling in energy homeostasis. Neuropharmacology (2015) 0.76
On the Role of Histamine Receptors in the Regulation of Circadian Rhythms. PLoS One (2015) 0.76
Proxyfan acts as a neutral antagonist of histamine H3 receptors in the feeding-related hypothalamic ventromedial nucleus. Br J Pharmacol (2012) 0.75
Some environmental contaminants influence motor and feeding behaviors in the ornate wrasse (Thalassoma pavo) via distinct cerebral histamine receptor subtypes. Environ Health Perspect (2005) 0.75
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell (1999) 9.84
Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 5.89
Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature (1998) 3.38
Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science (1996) 3.28
Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev (1990) 2.33
Histaminergic transmission in the mammalian brain. Physiol Rev (1991) 2.28
Uncoupling proteins 2 and 3: potential regulators of mitochondrial energy metabolism. Diabetes (2000) 2.06
Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol (1999) 1.91
Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem (2000) 1.81
Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature (1997) 1.79
Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol (1999) 1.77
Molecular pharmacological aspects of histamine receptors. Pharmacol Ther (1995) 1.47
Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A (1996) 1.43
Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Behavioral characterization of mice lacking histamine H(3) receptors. Mol Pharmacol (2002) 1.26
Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol (1994) 1.20
Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci (1998) 1.07
Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol (1996) 1.06
Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol (1994) 1.04
Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res (1990) 1.02
Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes (2001) 1.01
Chronic central leptin infusion enhances insulin-stimulated glucose metabolism and favors the expression of uncoupling proteins. Diabetes (1998) 1.00
Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes (2001) 0.95
Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition (1997) 0.94
Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol (1989) 0.93
Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res (1993) 0.92
Altered serotonin and dopamine metabolism in the CNS of serotonin 5-HT(1A) or 5-HT(1B) receptor knockout mice. J Neurochem (2000) 0.92
Hypothalamic neuronal histamine regulates feeding circadian rhythm in rats. Brain Res (1994) 0.90
Histamine H3-receptor-mediated inhibition of calcitonin gene-related peptide release from cardiac C fibers. A regulatory negative-feedback loop. Circ Res (1996) 0.88
Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res (1998) 0.87
Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed. Br J Pharmacol (1995) 0.86
Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol (2001) 0.85
The blockade of H1 receptors attenuates the suppression of feeding and diuresis induced by inhibition of histamine catabolism. Pharmacol Biochem Behav (1998) 0.83
Inhibition of brain histamine synthesis increases food intake and attenuates vasopressin response to salt loading in rats. Methods Find Exp Clin Pharmacol (1994) 0.81
Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes (1999) 0.81
Histaminergic control of energy balance in rats. Brain Res Bull (1992) 0.81
Cytotoxicity of a series of mono- and di-substituted thiourea in freshly isolated rat hepatocytes: a preliminary structure-toxicity relationship study. Toxicology (1998) 0.80
The H3 receptor is involved in cholecystokinin inhibition of food intake in rats. Life Sci (2001) 0.80
Histamine receptor and its regulation of energy metabolism. Obes Res (1995) 0.78
Zucker obese rats: defect in brain histamine control of feeding. Brain Res (1992) 0.77
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol (2006) 4.07
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther (2010) 2.68
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther (2009) 2.50
Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem (2003) 2.36
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer (2004) 1.52
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Mol Cancer Ther (2010) 1.48
Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res (2006) 1.32
Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer (2009) 1.11
Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. Kidney Int (2003) 1.04
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein Sci (2007) 1.01
Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis. Gastroenterology (2009) 0.99
Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. J Biol Chem (2005) 0.98
Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A (2006) 0.95
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics (2008) 0.91
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling. Cancer Res (2009) 0.91
Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding. Acta Crystallogr D Biol Crystallogr (2010) 0.89
Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines. Mol Cancer (2009) 0.88
Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med (2008) 0.88
Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers. Genomics (2009) 0.87
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther (2009) 0.87
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors. Bioorg Med Chem Lett (2009) 0.84
Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology (2013) 0.82
Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples. Mol Cancer (2011) 0.82
Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet (2010) 0.82
Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer. BMC Genomics (2009) 0.80
Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci (2006) 0.80
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo. Invest New Drugs (2010) 0.78
Simultaneous fluorometric measurement of histamine and tele-methylhistamine levels in rodent brain by high-performance liquid chromatography. Anal Biochem (2004) 0.77
Generation and characterization of highly constitutive active histamine H3 receptors. J Pharmacol Exp Ther (2003) 0.77
Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo. Cell Cycle (2010) 0.76
Impaired drinking response in histamine H3 receptor knockout mice following dehydration or angiotensin-II challenge. Pharmacol Biochem Behav (2006) 0.75
[Novel anti-cancer compounds targeting the cell cycle]. Nihon Yakurigaku Zasshi (2009) 0.75
High-throughput assay for long chain fatty acyl-CoA elongase using homogeneous scintillation proximity format. Assay Drug Dev Technol (2009) 0.75